K Otsu1, R Guo, S C Dreskin. 1. Division of Allergy and Clinical Immunology and Departments of Medicine and Immunology, University of Colorado Denver, Aurora, CO, USA.
Abstract
BACKGROUND: Ara h 2 and Ara h 6 are moderately homologous and highly potent peanut allergens. OBJECTIVE: To identify IgE-binding linear epitopes of Ara h 6, compare them to those of Ara h 2, and to stratify binding based on clinical histories. METHODS: Thirty highly peanut-allergic subjects were stratified by clinical history. Sera were diluted to contain the same amount of anti-peanut IgE. IgE binding to overlapping 20-mer peptides of Ara h 2 and Ara h 6 was assessed using microarrays. RESULTS: Each subject had a unique IgE-binding fingerprint to peptides; these data were coalesced into epitope binding. IgE from subjects with a history of more severe reactions (n = 19) had a smaller frequency of binding events (BEs) for both Ara h 2 (52 BEs of 152 (19X8epitopes) possible BEs and Ara h 6 (13 BEs of 133 (19X7 epitopes) possible BEs) compared to IgE from those with milder histories (n = 11) (Ara h 2: 47 BEs of 88 (11X8 epitopes) possible BEs, P < 0.01; Ara h 6: 25 BEs of 77 (11X7 epitopes) possible BEs, P < 0.001). Using an unsupervised hierarchal cluster analysis, subjects with similar histories tended to cluster. We have tentatively identified a high-risk pattern of binding to peptides of Ara h 2 and Ara h 6, predominantly in subjects with a history of more severe reactions (OR = 12.6; 95% CI: 2.0-79.5; P < 0.01). CONCLUSIONS AND CLINICAL RELEVANCE: IgE from patients with more severe clinical histories recognize fewer linear epitopes of Ara h 2 and Ara h 6 than do subjects with milder reactions and bind these epitopes in characteristic patterns. Close examination of IgE binding to epitopes of Ara h 2 and Ara h 6 may have prognostic value.
BACKGROUND:Arah 2 and Arah 6 are moderately homologous and highly potent peanut allergens. OBJECTIVE: To identify IgE-binding linear epitopes of Arah 6, compare them to those of Arah 2, and to stratify binding based on clinical histories. METHODS: Thirty highly peanut-allergic subjects were stratified by clinical history. Sera were diluted to contain the same amount of anti-peanutIgE. IgE binding to overlapping 20-mer peptides of Arah 2 and Arah 6 was assessed using microarrays. RESULTS: Each subject had a unique IgE-binding fingerprint to peptides; these data were coalesced into epitope binding. IgE from subjects with a history of more severe reactions (n = 19) had a smaller frequency of binding events (BEs) for both Arah 2 (52 BEs of 152 (19X8epitopes) possible BEs and Arah 6 (13 BEs of 133 (19X7 epitopes) possible BEs) compared to IgE from those with milder histories (n = 11) (Arah 2: 47 BEs of 88 (11X8 epitopes) possible BEs, P < 0.01; Arah 6: 25 BEs of 77 (11X7 epitopes) possible BEs, P < 0.001). Using an unsupervised hierarchal cluster analysis, subjects with similar histories tended to cluster. We have tentatively identified a high-risk pattern of binding to peptides of Arah 2 and Arah 6, predominantly in subjects with a history of more severe reactions (OR = 12.6; 95% CI: 2.0-79.5; P < 0.01). CONCLUSIONS AND CLINICAL RELEVANCE: IgE from patients with more severe clinical histories recognize fewer linear epitopes of Arah 2 and Arah 6 than do subjects with milder reactions and bind these epitopes in characteristic patterns. Close examination of IgE binding to epitopes of Arah 2 and Arah 6 may have prognostic value.
Authors: H S Porterfield; K S Murray; D G Schlichting; X Chen; K C Hansen; M W Duncan; S C Dreskin Journal: Clin Exp Allergy Date: 2009-05-11 Impact factor: 5.018
Authors: Inmaculada Cerecedo; Javier Zamora; Wayne G Shreffler; Jing Lin; Ludmilla Bardina; Ma Carmen Dieguez; Julie Wang; Alfonso Muriel; Belén de la Hoz; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2008-09 Impact factor: 10.793
Authors: Peter E Deak; Baksun Kim; Amina Abdul Qayum; Jaeho Shin; Girish Vitalpur; Kirsten M Kloepfer; Matthew J Turner; Neal Smith; Wayne G Shreffler; Tanyel Kiziltepe; Mark H Kaplan; Basar Bilgicer Journal: Proc Natl Acad Sci U S A Date: 2019-04-08 Impact factor: 11.205
Authors: Min Shen; Amit A Joshi; Raghu Vannam; Chandra K Dixit; Robert G Hamilton; Challa V Kumar; James F Rusling; Mark W Peczuh Journal: Chembiochem Date: 2018-01-04 Impact factor: 3.164
Authors: Stephen C Dreskin; Matthew Germinaro; Dominik Reinhold; Xueni Chen; Brian P Vickery; Michael Kulis; A Wesley Burks; Surendra S Negi; Werner Braun; Jeffery M Chambliss; Spodra Eglite; Caitlin M G McNulty Journal: Pediatr Allergy Immunol Date: 2019-10-21 Impact factor: 6.377
Authors: Clara San Bartolomé; Carmen Oeo-Santos; Pablo San Segundo-Acosta; Rosa Muñoz-Cano; Javier Martínez-Botas; Joan Bartra; Mariona Pascal Journal: Methods Mol Biol Date: 2021
Authors: Maria Suprun; Scott H Sicherer; Robert A Wood; Stacie M Jones; Donald Y M Leung; Alice K Henning; Peter Dawson; A Wesley Burks; Robert Lindblad; Robert Getts; Mayte Suárez-Fariñas; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2020-08-11 Impact factor: 10.793
Authors: Stephen C Dreskin; Stef J Koppelman; Sandra Andorf; Kari C Nadeau; Anjeli Kalra; Werner Braun; Surendra S Negi; Xueni Chen; Catherine H Schein Journal: J Allergy Clin Immunol Date: 2020-11-18 Impact factor: 10.793